Alpha-Synuclein: Adding Precision to Neurodegenerative Testing
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Alpha-Synuclein: Adding Precision to Neurodegenerative Testing
-
Narrated by:
-
Written by:
About this listen
In this episode of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, discusses the how and why of making precise clinical diagnosis of neurodegenerative diseases with Russ Lebovitz, MD, PhD, co-founder and CEO of Amprion.
Among the topics they discuss:
- The critical importance of making accurate diagnoses of neurodegenerative diseases
- Why alpha-synuclein is an accurate biomarker for a number of degenerative diseases, including Alzheimer’s
- How adding neurodegenerative testing to the routine diagnostic menu would benefit patients and their caregivers
- Why we’re entering a neurological healthcare “golden age”
adbl_web_anon_alc_button_suppression_c
No reviews yet